This new diagnosis represents a dramatic shift in thyroid pathology where an estimated 61% of lesions previously classified as FVPTCs will now be classified as NIFTP, thus decreasing the percentage of “malignancies” on final pathology compared with FNA. On pre-operative cytology, NIFTP is associated with FNA Bethesda Category III, IV, V, or VI in 15, 56, 27, and 2% of tumor samples, respectively (71). As a consequence, this has created a shift in the malignancy rate associated with each Bethesda category. Strickland et al. evaluated a cohort of 655 FNAs with subsequent resection specimens (72). When taking into account the new NIFTP diagnosis, indeterminate, and suspicious FNA samples of Bethesda III, IV, and V had an absolute decrease in rate of malignancy by 17.6, 8.0, and 41.5%, respectively (72). Similarly, Faquin et al. reported an absolute decrease in rate of malignancy in Bethesda III, IV, and V by 13.6, 15.1, and 23.4%, respectively (73).